Henry Chambers, MD

Phone: 415-206-5437
UCSF Box: 0811
Email: hchambers@medsfgh.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
Phase III Study: Safety & Efficacy of Daptomycin Compared to Conventional Therapy in the Treatment of Subjects w/ infective endocarditis or bacteremia due to Staphylococcus aureus PPD Inc. United States Opportunistic Infection
Proposed Experiments to Study Emergence of Antimicrobial Resistance in Methicillin- Resistant Strains of Staphylococcus aureus Ortho-McNeil Pharmaceutical Corporation United States Zoonosis, Emerging Disease, and Drug Resistance
Penicillin Interactive Proteins of Staphylococcus Aureus NIH National Institute of Allergy and Infectious Disease United States
Biology of Infectious Diseases Training Program [I] NIH National Institute of Allergy and Infectious Disease United States Training and Capacity Building
Applied Research on Antimicrobioal Resistance: Molecular Epidemiology of Community Methicillin-resistant Staphylococcus aureus (MRSA) Centers for Disease Control and Prevention (CDC) United States Zoonosis, Emerging Disease, and Drug Resistance
Protocol Development for a Phase 2 Study Evaluating the Safety and Feasibility of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia Ortho-McNeil, Inc United States Infectious Disease, Pharmacology and Drug Treatment
Phase 2 Study, Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia Ortho-McNeil, Inc United States Infectious Disease, Pharmacology and Drug Treatment
A Phase 2, Randomized, Open-Labeled Study on the Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia Accelere United States Infectious Disease, Pharmacology and Drug Treatment
Multidrug-Resistant CA-MRSA Infections Among HIV+ Persons: CA AIDS Grant ID07-REI-129 Los Angeles Biomedical Research Institute United States Infectious Disease, Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Epidemiology and Surveillance
Tetrezolid vs. Daptomycin and Vancomycin for Treatment of Experimental Staphylococcus aureus Trius Therapeutics, Inc United States Infectious Disease, Pharmacology and Drug Treatment
Ceftobiprole vs. Daptomycin and Linezolid for Treatment of Experimental Staph. aureus Endocarditis in Rabbits Johnson & Johnson United States Infectious Disease, Pharmacology and Drug Treatment
Rifabutin Based Therapy for Eradication of Staph Carriage in HIV-Infected Individuals with Prior Skin Structure Infections Pfizer United States HIV/AIDS, Opportunistic Infection
Prevention Umbrella for MSM in the Americas Public Health Foundation Enterprises, Inc. Brazil; Peru HIV/AIDS, Risk Reduction and Prevention
Epidemiologic Analysis of Data from Project Aware to Determine the Impact of Different HIV Testing Strategies on Risk Behaviors and STD Rates among HIV-Uninfected MSM Public Health Foundation Enterprises, Inc. United States HIV/AIDS
Efficacy Evaluation and Safety of Single-dose IV Oritavancin vs. IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection (SOLO I) PPD Inc. United States Infectious Disease
Biology of Infectious Diseases Training Program [II] NIH National Institute of Allergy and Infectious Disease United States Training and Capacity Building
Novel Mechanisms of Beta-Lactam Resistance in Staph aureus NIH National Institute of Allergy and Infectious Disease United States Zoonosis, Emerging Disease, and Drug Resistance
Prevention Umbrella for MSM in the Americas Public Health Foundation Enterprises, Inc. Brazil; Peru HIV/AIDS
Antibacterial Resistance Leadership Group (ARIG) Duke University United States Zoonosis, Emerging Disease, and Drug Resistance, Systematic Reviews and Guideline Development
A Clinical Trial for Uncomplicated Skin Infections in Areas of Epidemic Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) NIH National Institute of Allergy and Infectious Disease United States Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Blood Stream Infections due to Staphylococci. Duke University United States
Novel Mechanisms of Beta-Lactam Resistance in Staph Aureus NIH National Institute of Allergy and Infectious Disease United States Noncommunicable and/or Chronic Disease, Risk Reduction and Prevention
Study for Sample Acquisition for Patients Diagnosed with S. aureus Bacteremia Genentech, Inc. United States Infectious Disease, Drug and Diagnostics Development, Epidemiology and Surveillance
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus, Continuation A120553 NIH National Institute of Allergy and Infectious Disease United States Zoonosis, Emerging Disease, and Drug Resistance